The Pelage solution
A novel, non-invasive, topical small molecule drug platform that activates stem cells in the hair follicles directly to stimulate robust hair growth. By targeting an intrinsic metabolic switch in hair follicles, Pelage’s platform restores the hair follicle’s natural ability to grow hair.
How our drug works:
Hair follicles naturally cycle through
periods of rest and growth.
This process is governed by hair
follicle stem cells.
Over time, due to age, genetics, stress, hormones, and other factors, hair follicle stem cells can become "stuck" and unable to activate a new hair follicle growth cycle.
PP405 activates dormant hair follicle stem cells, restoring the natural regenerative capacity of the follicle and activating new hair growth in previously bald areas.
Selected Publications and Presentations
- American Academy of Dermatology 2024 Annual Meeting. Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo.
- Experimental Dermatology. Inhibition of pyruvate oxidation as a versatile stimulator of the hair cycle in models of alopecia
- Nature Cell Biology. Lactate dehydrogenase activity drives hair follicle stem cell activation
PP405 - the first treatment
designed specifically for hair loss
Androgenetic Alopecia
Also known as pattern hair loss, the most common type of hair loss in men and women. Caused by a combination of genetics, hormones, age, and environmental factors.
Drug-induced Alopecia
Hair loss caused by certain medications—most notably chemotherapy drugs used in cancer treatment.
Telogen Effluvium
Hair loss due to stressors such as illness, childbirth, menopause, and weight loss.
PP405 Clinical Trials
Interested in our clinical trials? We’d love to keep you informed about upcoming studies. Register your interest and, as information becomes available, our team will reach out to share details about upcoming studies, eligibility, and how you may be able to take part.